BD Veritor™ System for Rapid Detection of SARS-CoV-2,  and Flu A+B Testing

BD Veritor™ Plus System for Flu A + B

The BD Veritor™ System for Rapid Detection of Flu A+B is a rapid chromatographic immunoassay. 

The system provides rapid, reliable results, and offers one-button functionality for workflow flexibility, allowing health care providers to confidently use the Analyzer.

BD Veritor™ System for Rapid Detection of SARS-CoV-2

The BD Veritor™ System for Rapid Detection of SARS‑CoV‑2 antigen test detects nucleoproteins from the SARS‑CoV‑2 virus in as little as 15 minutes, and can be conducted at the point-of-care.The system provides rapid, reliable results, and offers one-button functionality for workflow flexibility, allowing health care professionals to confidently use the Analyzer.

Click Here to learn more!

BD Veritor™ Plus System for Group A Strep

Rapid diagnosis and early antibiotic therapy for Group A Streptococcal infection are the best means of preventing medical complications and reducing the spread of the disease¹.

BD Veritor™ System for Rapid Detection Videos:

Trust BD for the digital difference

Watch this video to learn how BD Veritor™ Plus System offers a point-of-care testing solution that delivers unambiguous, digitally read results for SARS-CoV-2*, Flu A+B, Group A Strep, and RSV. It offers:

• An easy-to-use device — the BD Veritor™ Plus Analyzer — that simplifies implementation and presents rapid, reliable results digitally.
• A range of assays to identify the relevant path to care for symptomatic patients so they can take their next steps with more confidence.

BD Veritor streamlines testing and reporting through its workflow services. The testing platform can be digitally integrated to provide a digital workflow for patient registration, report results to state/federal officials when required, and communicate results directly to the patient.

       *Under an Emergency Use Authorization (EUA) from the FDA

BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2

Learn about the BD Veritor System for the Rapid Detection of SARS-CoV-2 with the BD Veritor Plus Analyzer. The BD portable Veritor Plus Portable Analyzer is the point-of-care system used to test for flu or strep. Now that same system can be used for the detection of SARS-CoV-2 Covid-19 antigens, providing results in 15 minutes. 

Performing COVID-19 Testing

Watch the video to your right to learn how to perform rapid Covid-19 (SARS-CoV-2) testing with the BD Veritor™ Plus System.

COVID-19 and Flu A+B Testing

This video helps you learn about rapid COVID-19 and Flu A+B testing with the BD Veritor™ Plus System.

BD Veritor™ Plus System - Keys to Successful Testing

This video explains that following a set of best practices when using your BD Veritor™ Plus System is critical to ensure the highest degree of accuracy possible

BD Veritor Plus Analyzer System Instructional Videos 

Nasal Swab Collection:

Processing Flu A + B with Veritor:

Throat Swab Collection:

Processing Strep with Veritor:

Additional tools and resources:

• Pharmacy FAQs
  • Want to get your questions answered? Click Here to learn more!

• Patient Engagement Materials
  • Pharmacies can make Flu and Strep throat testing accessible, thus helping to prevent outbreaks, the spread of illness, and reduce the use of unnecessary antibiotics. Check it out here!

• Checklist of Requirements
  • CLIA - Waiver Certification
  • CPA - Practice Agreement
  • Get Paid - Reimbursement

EUA related information:

* The intended use of the BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 assay only includes those who are suspected of COVID-19 by their health care providers within the first five days on the onset of symptoms.

• This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA for use by authorized laboratories
• This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and
• This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner

Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C §263a, that meet the requirements to perform moderate, high or waived complexity tests.  This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

• EUA letter
• IFU
• HCP fact sheet
• Patient fact sheet